The Motley Fool's Market Checkup drills down on the hottest headlines and biggest market movers in the health-care sector. This episode -- featuring a special guest appearance by Dan Caplinger, The Motley Fool's director of investment planning -- highlights a biotech stock that popped 40%, gives a full examination of the Affordable Care Act's debut week, and finishes off with two stocks poised to profit from Obamacare.

In the following video, Fool health-care analyst David Williamson and Dan talk with Fool health-care bureau chief Max Macaluso about what didn't work with this week's rollout of Obamacare's health-insurance exchanges. David starts by observing that glitches in the exchanges' websites that stemmed from high traffic levels led to some problems for visitors trying to get information. He notes in particular that Xerox (NYSE:XRX) has been working with the Nevada health-care exchange to keep the website up and running even with the huge traffic volumes hitting its website.

Dan points out that troubles with websites led to a relatively small number of applications actually getting finalized, although applicants still have months before hitting the open-enrollment deadline. Moreover, Dan reminds viewers that similar problems arose during the launch of Medicare Part D prescription drug coverage, yet that program has been hugely successful and popular after the government worked those issues out. Dan concludes that given time, Obamacare's tech problems will get resolved and won't endanger its long-term success.

Neither David Williamson, Dan Caplinger, nor Max Macaluso, Ph.D. has any position in any stocks mentioned, nor does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.